{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:50:25Z","timestamp":1762509025990,"version":"3.40.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the treatment efficacy and the risk of adverse events of imiquimod for cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VAIN), compared with placebo or no intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DATA SOURCES:<\/jats:title>\n            <jats:p>We searched Cochrane, PubMed, ISRCTN registry, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to November 23, 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n            <jats:p>We included randomized controlled trials and prospective nonrandomized studies with control arms that investigated the efficacy of imiquimod for histologically confirmed CIN or VAIN. The primary outcomes were histologic regression of the disease (primary efficacy outcome) and treatment discontinuation due to side effects (primary safety outcome). We estimated pooled odds ratios (ORs) of imiquimod, compared with placebo or no intervention. We also conducted a meta-analysis of the proportions of patients with adverse events in the imiquimod arms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n            <jats:p>Four studies contributed to the pooled OR for the primary efficacy outcome. An additional four studies were available for meta-analyses of proportions in the imiquimod arm. Imiquimod was associated with increased probability of regression (pooled OR 4.05, 95% CI 2.08\u20137.89). Pooled OR for CIN in the three studies was 4.27 (95% CI 2.11\u20138.66); results of one study were available for VAIN (OR, 2.67, 95% CI 0.36\u201319.71). Pooled probability for primary safety outcome in the imiquimod arm was 0.07 (95% CI 0.03\u20130.14). The pooled probabilities (95% CI) of secondary outcomes were 0.51 (0.20\u20130.81) for fever, 0.53 (0.31\u20130.73) for arthralgia or myalgia, 0.31 (0.18\u20130.47) for abdominal pain, 0.28 (0.09\u20130.61) for abnormal vaginal discharge or genital bleeding, 0.48 (0.16\u20130.82) for vulvovaginal pain, and 0.02 (0.01\u20130.06) for vaginal ulceration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Imiquimod was found to be effective for CIN, whereas data on VAIN were limited. Although local and systemic complications are common, treatment discontinuation is infrequent. Thus, imiquimod is potentially an alternative therapy to surgery for CIN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SYSTEMATIC REVIEW REGISTRATION:<\/jats:title>\n            <jats:p>PROSPERO, CRD42022377982.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000005256","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T01:09:39Z","timestamp":1688692179000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia"],"prefix":"10.1097","volume":"142","author":[{"given":"Yoshihide","family":"Inayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orestis","family":"Efthimiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki A.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ijd.13235","article-title":"Imiquimod in dermatology: an overview","volume":"55","author":"Hanna","year":"2016","journal-title":"Int J Dermatol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jlb.55.2.234","article-title":"Cytokine induction in mice by the immunomodulator imiquimod","volume":"55","author":"Reiter","year":"1994","journal-title":"J Leukoc Biol"},{"issue":"suppl 2","key":"R3-20250423","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Schon","year":"2007","journal-title":"Br J Dermatol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(22)00469-X","article-title":"Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial","volume":"399","author":"Trutnovsky","year":"2022","journal-title":"The Lancet"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/AOG.0000000000001713","article-title":"Management of vulvar intraepithelial neoplasia. Committee Opinion No. 675. American College of Obstetricians and Gynecologists","volume":"128","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/jdv.18102","article-title":"2021 European guideline for the management of vulval conditions","volume":"36","author":"van der Meijden","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2017.09.020","article-title":"Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis","volume":"218","author":"Tranoulis","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"suppl 1","key":"R8-20250423","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ijgo.12191","article-title":"Treatment of cervical intraepithelial lesions","volume":"138","author":"Castle","year":"2017","journal-title":"Int J Gynecol Obstet"},{"key":"R9-20250423","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012847","article-title":"Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease","author":"Kyrgiou","year":"2017","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/AOG.0000000000004384","article-title":"Topical imiquimod for the treatment of high-grade squamous intraepithelial lesions of the cervix: a randomized controlled trial","volume":"137","author":"Fonseca","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","article-title":"Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial","volume":"120","author":"Grimm","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0000000000000414","article-title":"Topical imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC-3): a nonrandomized multicenter study","volume":"45","author":"Hendriks","year":"2022","journal-title":"J Immunother"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.currproblcancer.2021.100792","article-title":"Recurrence of high-grade vaginal intraepithelial neoplasia after various treatments","volume":"46","author":"Boonlikit","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/gyno.2001.6401","article-title":"Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia","volume":"83","author":"Dodge","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3802\/jgo.2019.30.e20","article-title":"Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia","volume":"30","author":"Bogani","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.3802\/jgo.2018.29.e6","article-title":"Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases","volume":"29","author":"Kim","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2020.09.031","article-title":"Imiquimod for vaginal intraepithelial neoplasia 2-3: a systematic review and meta-analysis","volume":"160","author":"Inayama","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.3390\/jcm10245777","article-title":"Comparison of conservative treatment of cervical intraepithelial lesions with imiquimod with standard excisional technique using LLETZ: a randomized controlled trial","volume":"10","author":"Cokan","year":"2021","journal-title":"J Clin Med"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/ijc.30275","article-title":"Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management","volume":"139","author":"Tainio","year":"2016","journal-title":"Int J Cancer"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.7326\/M22-1507","article-title":"The impact of the COVID-19 pandemic and associated control measures on the mental Health of the general population: a systematic review and dose-response meta-analysis","volume":"175","author":"Salanti","year":"2022","journal-title":"Ann Intern Med"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","article-title":"Practical guide to the meta-analysis of rare events","volume":"21","author":"Efthimiou","year":"2018","journal-title":"Evid Based Ment Health"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.tjog.2012.09.006","article-title":"Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical\/vaginal intraepithelial neoplasia","volume":"51","author":"Lin","year":"2012","journal-title":"Taiwanese J Obstet Gynecol"},{"key":"R28-20250423","first-page":"317","article-title":"Assessment of the treatment with imiquimod in persistent infection by human papillomavirus with the polymerase chain reaction method [in Spanish]","volume":"74","author":"Hern\u00e1ndez Quijano","year":"2006","journal-title":"Ginecol Obstet Mex"},{"key":"R31-20250423","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12885-018-4510-7","article-title":"TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial","volume":"18","author":"van de Sande","year":"2018","journal-title":"BMC Cancer"},{"key":"R35-20250423","doi-asserted-by":"crossref","first-page":"42.e1","DOI":"10.1016\/j.ajog.2011.06.105","article-title":"Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia","volume":"206","author":"Pachman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R36-20250423","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-017-3108-9","article-title":"Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial","volume":"17","author":"Koeneman","year":"2017","journal-title":"BMC Cancer"},{"key":"R37-20250423","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2022.01.033","article-title":"Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: multicenter, randomized controlled trial","volume":"165","author":"Polterauer","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R38-20250423","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jdcr.2019.04.015","article-title":"Imiquimod-induced effluvium after intravaginal application for treatment of cervical intraepithelial neoplasia","volume":"5","author":"Borst","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R39-20250423","first-page":"104","article-title":"A case report and literature review of delayed telogen effluvium after topical imiquimod use in treating a cervical high-grade squamous intraepithelial lesion","volume":"43","author":"Cokan","year":"2022","journal-title":"Eur J Gynaecol Oncol"},{"key":"R41-20250423","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/ijgc-2022-004213","article-title":"The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia","volume":"33","author":"Kesic","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"R42-20250423","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdin.2022.01.010","article-title":"Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod","volume":"7","author":"Bhatia","year":"2022","journal-title":"JAAD Int"},{"key":"R43-20250423","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R44-20250423","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1016\/j.crwh.2019.e00105","article-title":"Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - a case series","volume":"21","author":"Wouters","year":"2019","journal-title":"Case Rep Women's Health"},{"key":"R45-20250423","first-page":"95","article-title":"Treatment of residual or recurrent CIN with topical imiquimod: a retrospective study","volume":"4","author":"van de Sande","year":"2020","journal-title":"Arch Microbiol Immunol"},{"key":"R46-20250423","first-page":"3031","article-title":"Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%","volume":"7","author":"Diaz-Arrastia","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:00:51Z","timestamp":1745438451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005256"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005256","relation":{},"ISSN":["0029-7844"],"issn-type":[{"type":"print","value":"0029-7844"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"2023-02-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}